MD Anderson Cancer Center

MD Anderson Cancer Center, located in Houston, Texas, is one of the largest cancer treatment and research institutions globally, dedicated to the mission of eliminating cancer. Employing nearly 20,000 individuals, including over 1,600 faculty members, it operates as a degree-granting academic institution while providing a wide range of cancer treatment services. The center spans more than 25 buildings in Houston and Central Texas, facilitating extensive research and advanced medical care in the fight against cancer.

Michael Brown

Project Director and Chief of Staff

William Simeone Jr.

Vice President for Operations and Chief Quality Officer

1 past transactions

Magnolia Neurosciences

Series A in 2018

Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.